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Background-—Sympathetic and parasympathetic influences on heart rate (HR), which are governed by baroreflex mechanisms, are
integrated at the cardiac sinus node through hyperpolarization-activated cyclic nucleotide–gated channels (HCN4). We
hypothesized that HCN4 blockade with ivabradine selectively attenuates HR and baroreflex HR regulation, leaving baroreflex
control of muscle sympathetic nerve activity intact.
Methods and Results-—We treated 21 healthy men with 297.5 mg ivabradine or placebo in a randomized crossover fashion. We
recorded electrocardiogram, blood pressure, and muscle sympathetic nerve activity at rest and during pharmacological baroreflex
testing. Ivabradine reduced normalized HR from 65.98.1 to 58.46.2 beats per minute (P<0.001) with unaffected blood
pressure and muscle sympathetic nerve activity. On ivabradine, cardiac and sympathetic baroreflex gains and blood pressure
responses to vasoactive drugs were unchanged. Ivabradine aggravated bradycardia during baroreflex loading.
Conclusions-—HCN4 blockade with ivabradine reduced HR, leaving physiological regulation of HR and muscle sympathetic nerve
activity as well as baroreflex blood pressure buffering intact. Ivabradine could aggravate bradycardia during parasympathetic
activation.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00865917. ( J Am Heart Assoc. 2016;5:
e002674 doi: 10.1161/JAHA.115.002674)
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M edication effects on human cardiovascular regulationare difficult to predict based on preclinical and clinical
investigations. Drugs could interfere with cardiovascular
regulation in brain or periphery directly or through secondary
baroreflex-mediated adjustments in heart rate (HR) and
vascular tone. High-fidelity phenotyping during infusion of
vasoactive medications can be used to detect drug effects on
human cardiovascular control that could otherwise go unde-
tected. Ivabradine inhibits hyperpolarization-activated cyclic
nucleotide–gated potassium channel 4 (HCN4). HCN4 gener-
ates “funny” pacemaker f currents (If) promoting slow diastolic
depolarization and cardiac rhythm generation.1 Intracellular
cyclic adenosine monophosphate (cAMP) modulates If
2, and
b-adrenergic stimulation augments cAMP, thereby increasing
HCN4 conductivity and HR. Cholinergic stimulation elicits the
opposite response. Given HCN4’s important role in autonomic
HR adjustments, pharmacological HCN4 inhibition could pro-
foundly affect human cardiovascular regulation. In fact,
chronotropic competence is reduced3 or absent4 in mutated
HCN4 channels unresponsive to cAMP. Conversely, blockade of
HCN4 channels on baroreceptor sensory neurons increased
their excitability,5,6 which would tend to facilitate afferent
baroreflex signaling and baroreflex function. The issue is
relevant because ivabradine7,8 is used in the treatment of heart
failure9 and angina pectoris10; however, the influences of HCN4
on human cardiovascular autonomic regulation have not been
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studied, aside from noninvasive baroreflex assessment of
profound sympathetic activation.11 Ivabradine is an open-
channel blocker12 producing “frequency-dependent” or “use-
dependent” HCN4 inhibition,13 thus ivabradine may be more
effective at increased HR.14 We tested the hypothesis that
pharmacological HCN4 blockade with ivabradine affects
baroreflex HR regulation in healthy participants such that HR
is reduced at a given blood pressure (BP). Moreover, we
assessed whether ivabradine would interfere with baroreflex
regulation of HR and sympathetic efferent traffic to resistance
vessels and whether or not baroreflex BP buffering is perturbed.
Finally, we evaluated whether or not in vivo responses mirror
ivabradine’s use-dependent pharmacology.
Methods
Participants
Healthy men (aged 18–40 years) with a body mass index
between 18 and 30 kg/m2 and a resting HR ≥60 beats per
minute (bpm) were eligible for this study. Preexisting diseases
were ruled out through a detailed history, medical examina-
tion, 12-lead ECG, BP recordings, and blood sampling for
routine laboratory measurements. All procedures were in
accordance with the Helsinki Declaration of 1975 (as revised
in 1983). A national competent authority and the local internal
review board approved the studies. Written informed consent
was obtained before inclusion.
Study Design and Protocol
This randomized, double-blind, 2-period, 2-sequence, crossover
study was conducted at 2 sites (Experimental Clinical Research
Center, Charite Medical University, Berlin, Germany, and
Institute of Clinical Pharmacology, Hannover Medical School,
Hannover, Germany). Randomization for study drug sequence
(randomization block size: 6) and manufacturing and labeling of
blinded medications was done centrally by the pharmacy of the
Charite Medical University. Medications were prepared as
identical capsules in neutral containers labeled with the
randomization code and a visit identifier. After inclusion,
participants were consecutively allocated to the next available
randomization number. Adherence to randomized medication
sequence was secured by following the predefined numeric
sequence of the visits. Consequently, participants and inves-
tigators remained fully blinded until the database had been
locked, double checked, and transferred to the Institute of
Biostatistics at Hannover Medical School. The study was
registered at ClinicalTrials.gov (identifier NCT00865917).
On 2 separate occasions, participants ingested maximally
recommended doses of ivabradine (7.5 mg) or matching
placebo 13 hours and 1 hour before testing. The washout
period between study days was at least 3 weeks. Testing was
conducted between 8 and 11 AM in a quiet laboratory at an
ambient temperature of 22 to 23°C.
An ECG was continuously recorded (Niccomo, Medis GmbH)
for HR determination. Recumbent systolic BP (SBP), mean BP,
and diastolic arterial BP were measured with an automated
oscillometric device (Dinamap; GE/Critikon). We obtained
blood samples after at least 30 minutes of rest for plasma
catecholamine determination with high-pressure liquid chro-
matography and consecutive electrochemical detection.15
Stroke volume and cardiac output were obtained using an inert
gas rebreathing technique (Innocor; Innovision). Muscle sym-
pathetic nerve activity (MSNA) was recorded from the right
peroneal nerve (Nerve Traffic Analyzer 662C-3; Biomedical
Engineering Department, University of Iowa, Iowa City, IA), as
described previously.16 Data were analog-to-digital converted
and analyzed using a program written by one of the authors
(A.D.). We determined the followingMSNA parameters from the
integrated nerve signal: burst frequency, or the number of
MSNA bursts per minute; burst incidence, or the number of
bursts per 100 heart beats; and total activity, or the area under
the bursts per minute as arbitrary units per minute.
Following a resting period of at least 30 minutes, we
obtained resting baseline recordings in the supine position.
After taking blood samples and measuring cardiac output, we
performed a pharmacological baroreflex assessment using the
nitric oxide donor sodium nitroprusside (vasodilator) and the
a1-adrenoceptor agonist phenylephrine (vasoconstrictor).
Incremental infusions were given over periods of 6 minutes
per dose step. Dose incrementation was stopped after the
maximumdose of 2.1 lg/kg perminute had been reached, SBP
had changed by >25 mm Hg, or HR had dropped <40 bpm.
End Points
Main end points of the study were normalized HR (ie, HR at a
given BP) and resting MSNA burst frequency during supine
rest. Exploratory end points served to further characterize
hemodynamic and autonomic responses to ivabradine at rest
and during pharmacologic baroreflex challenge: arterial BP,
stroke volume, cardiac output, total peripheral resistance,
plasma catecholamine levels, cardiac and sympathetic barore-
flex characteristics, and vasoactor sensitivity. The latter was
defined as SBP change per dose increment of sodium
nitroprusside and phenylephrine, respectively.
HR Normalization
Ivabradine is expected to change HR directly, but it may do so
also indirectly via baroreflexes through changes in BP. To
remove confounding baroreflex influences on resting HR, we
normalized HR before data unblinding (example in Figure 1):
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We transferred the relationship between RR intervals (RRIs)
and corresponding SBP values during pharmacological barore-
flex testing into a mathematical function by linear regression
or baroreflex curve fitting using a Boltzmann sigmoidal
function separately for the placebo and ivabradine condition
for each participant (sigmoidal curves in the example). Resting
SBP of both visits (vertical dotted lines in the Figure 1) were
averaged. The average served as shared common (standard)
pressure (vertical solid line in the figure). This standard
pressure was used as input (abscissa value) to the baroreflex
curve function to calculate normalized RRI and HR for each
visit separately (ordinate values).
Merged Baroreflex Curves
Baroreflex-mediated changes in the dependent parameters
(MSNA, RRI) were collected in 10-mm Hg bins separately for
placebo and ivabradine. Related bins for all participants were
merged. Using GraphPad Prism 5, a Boltzmann sigmoidal
function was fitted to these merged data, and 95% confidence
bands were calculated and plotted. Note that the bins for
lowest and highest BP are least occupied by values, thus their
weight in calculations of curve-fitting parameters and confi-
dence bands are small (Figure 6A and 6B).
Statistics
We expected to observe an ivabradine-related HR reduction by
6 bpm. With SD of 6.7 bpm in the group’s resting HR paired
differences, a=0.05, and 2-sided testing, 15 participants would
provide ≥80% statistical power to detect such a difference.17 We
included additional participants to allow for the meaningful
analysis of secondary and exploratory end points. According to a
prospective data analysis plan, primary and secondary end points
were analyzed using the Hills-Armitage approach.18 The method
allows period-adjusted therapy effect estimation, namely, calcu-
lation of period-adjusted P values for mean differences between
placebo and ivabradine data. To appreciate consistency of the
results, several sensitivity analyseswere performed (univariate1-
sample t tests and mixed-model analysis with participant as
random effect). Exploratory variables have been tested with t
tests for paired data and correlation analysis without adjust-
ments for multiple testing. A value of P<0.05 was considered
significant. If not otherwise indicated, data are expressed as
meanSD.
Results
We screened 26 men: 23 met inclusion and exclusion criteria
and entered the study. Twenty-one men completed both study
Figure 1. HR normalization procedure. The exam-
ple assumes lower SBP on ivabradine than on
placebo (118 vs 122 mm Hg). Related RRIs are
labeled “raw RRI.” The solid vertical line represents
mean SBP (120 mm Hg), which determines “nor-
malized RRI” values. Without normalization, ivabra-
dine’s effect on HR would have been
underestimated, as demonstrated by the smaller
difference between the 2 raw RRI values compared
with the normalized RRI values. HR indicates heart
rate; RRI, RR interval; SBP, systolic blood pressure.
Figure 2. CONSORT flow diagram of participant enrollment,
allocation, and analysis. IC indicates informed consent; IVA,
ivabradine; PLC, placebo
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visits (2 dropped out) (Figure 2). Microneurographic record-
ings were obtained in 18 participants on both days. In 3
participants, we failed to obtain a stable nerve recording
position at the second experimental day. The characteristics
of the participants were as follows: age 26.84.2 years,
height 1.820.06 m, body mass 79.810.5 kg, body mass
index 24.13.0 kg/m2, BP 1308/728 mm Hg, and HR
67.45.8 bpm. Two adverse events (insomnia, hyperhidrosis)
occurred during the study. The events were not judged to be
related to the study medication. There were no serious
adverse events.
Experimental data are shown in Table. If blockade
reduced resting HR with and without normalization for
prevailing BP (Figure 3A) (for HR normalization, see Meth-
ods). Ivabradine did not influence resting MSNA (Figure 4).
BP and stroke volume remained unchanged with a trend
toward reduced cardiac output (7.6%) and increased total
peripheral resistance (5.6%) on ivabradine. Plasma cate-
cholamine levels were similar under both conditions. SBP
sensitivity to sodium nitroprusside infusion was similar on
both study days with a trend toward reduced sensitivity
(improved BP buffering) to the vasoconstrictor phenylephrine
with If blockade (Figure 5). Ivabradine did not alter pharma-
cological baroreflex sensitivities, such as the cardiac
parasympathetic and vasoconstrictor sympathetic baroreflex
gains. If blockade dampens the increase in MSNA burst
frequency during higher sodium nitroprusside infusion rates,
namely, when high vasoconstrictor activity and elevated HR
co-occur (Figure 6A); however, HR-independent MSNA
parameters (ie, MSNA burst incidence and total activity)
were not altered by HCN4 blockade during pharmacological
baroreflex testing (data not shown). Ivabradine caused a
“parallel” upward shift of the cardiac baroreflex curve to
longer RRIs (Figure 6B). Consequently, RRI lengthening by
ivabradine was virtually independent of the prevailing HR
during pharmacological baroreflex testing.
Table. Hemodynamic, Sympathetic, Hormonal, and Baroreflex Parameters
Parameter Placebo Ivabradine P Value
Hemodynamics
HR, bpm 65.98.1 58.46.2 <0.001
HRP, bpm 52.77.4 47.35.5 <0.002
SBP, mm Hg 1238 1228 0.649
MBP, mm Hg 894 894 0.894
DBP, mm Hg 685 695 0.582
CO, L/min 7.741.60 7.191.15 0.071
SV, mL 11823 11818 0.899
TPR, dyns/cm5 956185 1010160 0.088
Sympathetic activity (MSNA bursts)
Frequency, bursts/min 28.47.9 26.26.7 0.221
Incidence, bursts/100 heart beats 46.011.3 45.312.1 0.575
Total activity, au 1.140.45 1.260.76 0.892
Hormones
Dopamine, pmol/L 6925 7014 0.520
Norepinephrine, pmol/L 1040500 910210 0.654
Epinephrine, pmol/L 13584 13264 0.553
Pharmacological baroreflex and vasoactor sensitivity
Cardiac BRG, ms/mm Hg 16.88.4 14.86.5 0.151
Sympathetic BRG, bursts/min/mm Hg 2.741.07 2.530.83 0.247
NTP sensitivity, mm Hg lg1 min1 kg1 7.96.4 6.24.6 0.158
PHE sensitivity, mm Hg lg1 min1 kg1 20.58.0 18.06.3 0.073
au indicates arbitrary units; BRG, baroreflex gain (ie, baroreflex sensitivity); CO, cardiac output; DBP, diastolic blood pressure; HR, normalized (baroreflex-corrected) heart rate; HRP,
normalized heart rate during parasympathetic activation; MBP, mean blood pressure; MSNA, muscle sympathetic nerve activity; NTP, sodium nitroprusside; PHE, phenylephrine; SBP,
systolic blood pressure; SV, stroke volume; TPR, total peripheral resistance.
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Participants with higher resting HR on placebo exhibited
more pronounced HR slowing on ivabradine, showing “use
dependence” (Figure 3B). Participants with HR below
56.5 bpm did not respond to If blockade. We observed a
similar pattern during baroreflex loading with phenylephrine
(Figure 3C and 3D); however, the HR at which ivabradine did
not slow HR further was only 44.2 bpm (ie, 12 bpm lower
during parasympathetic activation). Together, Figure 3B and
3D visualize ivabradine’s use-dependent characteristics; how-
ever, they also show, as does Figure 6B, that ivabradine and
parasympathetic activation are additive in terms of HR
reduction.
Discussion
We observed that HCN4 blockade with ivabradine reduces
HR, leaving baroreflex HR and MSNA regulation intact.
Although HCN4 is involved in transducing autonomic
activity at the sinus node level, baroreflex HR regulation
was preserved on ivabradine. The cardiac baroreflex curve
was parallel-shifted toward lower HR without reductions in
baroreflex gain or range. Similarly, baroreflex HR slopes
determined noninvasively by cross-spectral analysis or the
sequence method were unchanged with ivabradine in a
human model of cardiac sympathetic activation.11 Because
MSNA discharges occur during diastole when arterial
baroreceptors are unloaded, we expected reduced MSNA
frequencies with compensatory increases in sympathetic
action potentials within bursts; however, ivabradine-induced
HR reduction was not associated with resting MSNA
changes. Moreover, sympathetic baroreflex regulation was
virtually identical on placebo and on ivabradine considering
HR-independent MSNA measurements. Finally, BP
responses to vasoactive medications did not increase on
ivabradine, suggesting that baroreflex BP buffering remained
fully functional.19
Figure 3. Individual effects of HCN4 inhibition on HR. A, Effects of HCN4 inhibition on resting HR. Solid
and dashed lines denote HR decreases and increases, respectively. B, Ivabradine’s use dependence: HR
lowering is more pronounced in participants with higher resting HR. With resting values of 56.5 bpm,
ivabradine has no effect (unresponsive HR). C, Effects of HCN4 inhibition on HR during parasympathetic
activation (HRP) through baroreflex loading with phenylephrine. HRP was assessed as HR at the largest
individual phenylephrine dose that was reached on both study days. Solid and dashed lines denote HRP
decreases and increases, respectively. D, Participants with lower HRP on placebo exhibited a smaller
reduction in HRP with ivabradine. The observation is consistent with ivabradine’s use-dependent
pharmacology; however, parasympathetic activation shifted the unresponsive HR to 44.2 bpm, which
is 12 bpm lower compared with resting conditions (see panel B). bpm indicates beats per minute; HR,
heart rate.
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Together with previous studies in genetic animal models
and in patients with familial sinus bradycardia due to HCN4
mutations,3,20–23 our study provides new insight into HCN4’s
role in HR regulation. In patients with the 573X mutation,
HCN4 does not respond to cAMP.3 Nevertheless, HR
increased 50 bpm during exercise. Likewise, HR accelera-
tion to b-adrenoreceptor stimulation was intact in adult
HCN4-deleted mice24 and in a heterozygous knock-in model
rendering HCN4 cAMP insensitive.4 On ivabradine, chrono-
tropic competence in terms of HR acceleration and deceler-
ation over a wide HR range assessed through baroreflex
loading and unloading was unchanged. Consequently, If
cannot be the crucial mechanism transducing autonomic
signals at the level of the sinus node.
Cardiac pacemaker models are composed of several
clocks,25,26 raising questions about HCN4’s dominant role in
sinoatrial node automatism and rate regulation. Instead,
HCN4 may defend the sinus node against excess hyperpo-
larization,27 preventing bradycardia. Despite its use-depen-
dent pharmacology,12 indicated by larger HR reduction in
persons with higher resting HR, ivabradine aggravated
baroreflex-mediated bradycardia in our study. Moreover, in
the SIGNIFY study, almost 10 000 patients with stable
coronary artery disease received ivabradine doses up to
10 mg twice daily. Bradycardia and atrial fibrillation occurred
more often in the ivabradine group.28 Together with our
mechanism-oriented study, these observations translate the
preclinical concept that If is a defense mechanism against
excess bradycardia to humans. Using a similar approach, we
previously observed that a2-adrenoreceptor stimulation with
clonidine also disables physiological safeguards maintaining
HR.29
Our study has potential limitations. We did not investi-
gate responses to ivabradine under steady state conditions;
Figure 4. Effects of HCN4 inhibition on MSNA. A, Original recordings of 2 participants. B, Individual
changes in MSNA burst frequency, burst incidence, and total MSNA by ivabradine compared with placebo.
Total MSNA has been rescaled (920) for visual range harmonization among the 3 MSNA measures (also see
Table). au indicates arbitrary units; hb, heart beats; MSNA, muscle sympathetic nerve activity.
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however, we showed earlier that acute dosing 13 hours and
1 hour before measurements was sufficient to attain
ivabradine plasma concentrations in a therapeutic range.11
Furthermore, the drug’s bradycardic activity consists of an
initial rapid and subsequent relatively long duration of
action caused by the N-dealkylated metabolite and the
parent drug, respectively.30 On the other hand, the 3-week
washout period was more than twice the time required to
avoid carryover, according to the kinetics of the bradycardic
effect with repeated oral administration.30 Ivabradine’s
pharmacological interaction with HCN4 channels compli-
cates the interpretation of our study. As an open-channel
blocker, for example, ivabradine features use dependence
with trapping of the drug in the closed HCN4 channel.8
Furthermore, HCN4 is also expressed in the nervous
system, particularly in the thalamus,31 in spinal interneu-
rons,32 and in baroreflex afferents.5,6 MSNA is a sensitive
readout for changes in central autonomic regulation.33–35
Because MSNA did not change, confounding effects by
neural HCN4 inhibition is unlikely; however, diseases could
alter the ivabradine response. Blunted baroreflex function in
type 1 diabetic rats, for example, was associated with
increased HCN expression and cAMP sensitivity.6 Our
findings in healthy participants cannot be simply extrapo-
lated to patients. Finally, given the potential influence of
respiration on postganglionic sympathetic discharge, it
would have been desirable to also record and analyze
Figure 5. BP sensitivity to vasoactors. Effects of HCN4 inhibition
on BP sensitivity to infusion of the vasoconstrictor phenyle-
phrine (upper panel) and the vasodilator sodium nitroprusside (lower
panel) during placebo (open circles) and ivabradine (closed
circles). Note the trend toward improved baroreflex buffering of
BP increases on ivabradine (upper panel). BP indicates blood
pressure.
Figure 6. Interactions between ivabradine and arterial barore-
flexes. A, Sympathetic baroreflex: Although ivabradine may dampen
the increase in MSNA burst frequency during nitroprusside infusion
(ie, when high vasoconstrictor activity and elevated HR co-occur),
baroreflex curves are virtually identical if HR-independent MSNA
measures (burst incidence and total activity) are used (curves not
shown). B, Cardiac baroreflex: Ivabradine shifts (“offsets”) the
baroreflex curve upward (to longer RRIs) with virtually no effect on
slope or range. Shaded areas indicate 95% confidence bands. Note
that the bands do not overlap with high blood pressure, indicating
that baroreflex-mediated HR slowing is intensified by ivabradine.
DBP indicates diastolic blood pressure; HR, heart rate; MSNA,
muscle sympathetic nerve activity; RRI, RR interval; SBP, systolic
blood pressure.
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breathing, yet others did not observe effects of ivabradine
on respiratory rate either in healthy men36 or in patients
with chronic obstructive pulmonary disease.37
Conclusion
High-fidelity physiological phenotyping provides pharmacolog-
ical insight that could not be gained by routine HR and BP
measurements. We observed that HCN4 blockade with
ivabradine reduced HR but did not impair sympathetic or
parasympathetic baroreflex function. This feature preserves
baroreflex-dependent buffering of BP changes and aggravates
parasympathetically mediated HR reduction; therefore, ivab-
radine’s use dependence is not protective against marked
bradycardia. Our results could explain unfavorable responses
to ivabradine in recent clinical trials. Moreover, our findings
provide a better understanding of HCN4’s physiology in
humans, which could be applied to elucidate diseases
associated with perturbed HR regulation. Excess HCN4
conductivity, for example, could contribute to postural
tachycardia syndrome, a condition characterized by sinus
tachycardia with standing and a mismatch between cardiac
and vascular sympathetic activation.38,39 Indeed, HCN4
inhibition may improve symptoms of postural tachycardia
syndrome.40 Although gain-of-function mutations in the HCN4
gene have not been discovered, functional HCN4 gain of
function has been described in right atrial samples from
patients with chronic atrial fibrillation.41 Patients with heart
failure or coronary artery disease, who are currently being
considered for ivabradine treatment, also show redistribution
of sympathetic activity toward the heart with an associated
increase in HR.42,43
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